Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment

Traditional wisdom suggests that galectins play pivotal roles at different steps in cancer progression. Galectins are particularly well known for their ability to increase the invasiveness of cancer cells and their resistance to drug-induced cell death. They also contribute to the development of loc...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Samy Ajarrag, Yves St-Pierre
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	galectin brain tumors blood–brain barrier immunotherapy glioblastoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/961b88acfa3e4dd59772c4f6e67b27f3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:961b88acfa3e4dd59772c4f6e67b27f3
record_format	dspace
spelling	oai:doaj.org-article:961b88acfa3e4dd59772c4f6e67b27f32021-11-11T15:34:02ZGalectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment10.3390/cancers132155332072-6694https://doaj.org/article/961b88acfa3e4dd59772c4f6e67b27f32021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5533https://doaj.org/toc/2072-6694Traditional wisdom suggests that galectins play pivotal roles at different steps in cancer progression. Galectins are particularly well known for their ability to increase the invasiveness of cancer cells and their resistance to drug-induced cell death. They also contribute to the development of local and systemic immunosuppression, allowing cancer cells to escape the host’s immunological defense. This is particularly true in glioma, the most common primary intracranial tumor. Abnormally high production of extracellular galectins in glioma contributes to the establishment of a strong immunosuppressive environment that favors immune escape and tumor progression. Considering the recent development and success of immunotherapy in halting cancer progression, it is logical to foresee that galectin-specific drugs may help to improve the success rate of immunotherapy for glioma. This provides a new perspective to target galectins, whose intracellular roles in cancer progression have already been investigated thoroughly. In this review, we discuss the mechanisms of action of galectins at different steps of glioma progression and the potential of galectin-specific drugs for the treatment of glioma.Samy AjarragYves St-PierreMDPI AGarticlegalectinbrain tumorsblood–brain barrierimmunotherapyglioblastomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5533, p 5533 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	galectin brain tumors blood–brain barrier immunotherapy glioblastoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	galectin brain tumors blood–brain barrier immunotherapy glioblastoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Samy Ajarrag Yves St-Pierre Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment
description	Traditional wisdom suggests that galectins play pivotal roles at different steps in cancer progression. Galectins are particularly well known for their ability to increase the invasiveness of cancer cells and their resistance to drug-induced cell death. They also contribute to the development of local and systemic immunosuppression, allowing cancer cells to escape the host’s immunological defense. This is particularly true in glioma, the most common primary intracranial tumor. Abnormally high production of extracellular galectins in glioma contributes to the establishment of a strong immunosuppressive environment that favors immune escape and tumor progression. Considering the recent development and success of immunotherapy in halting cancer progression, it is logical to foresee that galectin-specific drugs may help to improve the success rate of immunotherapy for glioma. This provides a new perspective to target galectins, whose intracellular roles in cancer progression have already been investigated thoroughly. In this review, we discuss the mechanisms of action of galectins at different steps of glioma progression and the potential of galectin-specific drugs for the treatment of glioma.
format	article
author	Samy Ajarrag Yves St-Pierre
author_facet	Samy Ajarrag Yves St-Pierre
author_sort	Samy Ajarrag
title	Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment
title_short	Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment
title_full	Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment
title_fullStr	Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment
title_full_unstemmed	Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment
title_sort	galectins in glioma: current roles in cancer progression and future directions for improving treatment
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/961b88acfa3e4dd59772c4f6e67b27f3
work_keys_str_mv	AT samyajarrag galectinsingliomacurrentrolesincancerprogressionandfuturedirectionsforimprovingtreatment AT yvesstpierre galectinsingliomacurrentrolesincancerprogressionandfuturedirectionsforimprovingtreatment
_version_	1718435196444868608

Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment

Documents similaires